TFOS DEWS II Management and Therapy Report

被引:1048
作者
Jones, Lyndon [1 ]
Downie, Laura E. [2 ]
Korb, Donald [3 ]
Benitez-del-Castillo, Jose M. [4 ]
Dana, Reza [5 ]
Deng, Sophie X. [6 ]
Dong, Pham N. [7 ]
Geerling, Gerd [8 ]
Hida, Richard Yudi [9 ]
Liu, Yang [10 ]
Seo, Kyoung Yul [11 ]
Tauber, Joseph [12 ]
Wakamatsu, Tais H. [13 ]
Xu, Jianjiang [14 ]
Wolffsohn, James S. [15 ]
Craig, Jennifer P. [16 ]
机构
[1] Univ Waterloo, Sch Optometry & Vis Sci, Ctr Contact Lens Res, Waterloo, ON, Canada
[2] Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic, Australia
[3] Korb & Associates, Boston, MA USA
[4] Univ Complutense, Dept Ophthalmol, Madrid, Spain
[5] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA USA
[6] UCLA, Stein Eye Inst, Los Angeles, CA USA
[7] Vietnam Natl Inst Ophthalmol, Dept Corneal & External Dis, Hanoi, Vietnam
[8] Univ Hosp Duesseldorf, Dept Ophthalmol, Dusseldorf, Germany
[9] Univ Sao Paulo, Dept Ophthalmol, Santa Casa Sao Paulo, Sao Paulo, Brazil
[10] Massachusetts Eye & Ear, Schepens Eye Res Inst, Boston, MA USA
[11] Yonsei Univ, Med Coll, Dept Ophthalmol, Seoul, South Korea
[12] Tauber Eye Ctr, Kansas City, MO USA
[13] Univ Fed Sao Paulo, Sao Paulo Hosp, Paulista Sch Med, Dept Ophthalmol & Visual Sci, Sao Paulo, Brazil
[14] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol & Visual Sci, Shanghai, Peoples R China
[15] Aston Univ, Ophthalm Res Grp, Birmingham, W Midlands, England
[16] Univ Auckland, New Zealand Natl Eye Ctr, Dept Ophthalmol, Auckland, New Zealand
关键词
Dry eye disease; Dry eye workshop; Management; TFOS DEWS II; Therapy; DRY EYE DISEASE; MEIBOMIAN GLAND DYSFUNCTION; CORNEAL EPITHELIAL-CELLS; OCULAR SURFACE DISEASE; NERVE GROWTH-FACTOR; POLYUNSATURATED FATTY-ACIDS; AUTOLOGOUS SERUM EYEDROPS; PRIMARY SJOGRENS-SYNDROME; AMNIOTIC MEMBRANE TRANSPLANTATION; INTERLEUKIN-1 RECEPTOR ANTAGONIST;
D O I
10.1016/j.jtos.2017.05.006
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
The members of the Management and Therapy Subcommittee undertook an evidence-based review of current dry eye therapies and management options. Management options reviewed in detail included treatments for tear insufficiency and lid abnormalities, as well as anti-inflammatory medications, surgical approaches, dietary modifications, environmental considerations and complementary therapies. Following this extensive review it became clear that many of the treatments available for the management of dry eye disease lack the necessary Level 1 evidence to support their recommendation, often due to a lack of appropriate masking, randomization or controls and in some cases due to issues with selection bias or inadequate sample size. Reflecting on all available evidence, a staged management algorithm was derived that presents a step-wise approach to implementing the various management and therapeutic options according to disease severity. While this exercise indicated that differentiating between aqueous-deficient and evaporative dry eye disease was critical in selecting the most appropriate management strategy, it also highlighted challenges, based on the limited evidence currently available, in predicting relative benefits of specific management options, in managing the two dry eye disease subtypes. Further evidence is required to support the introduction, and continued use, of many of the treatment options currently available to manage dry eye disease, as well as to inform appropriate treatment starting points and understand treatment specificity in relation to dry eye disease subtype. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:575 / 628
页数:54
相关论文
共 1003 条
[41]  
Arrua M, 2015, Arch Soc Esp Oftalmol, V90, P112, DOI 10.1016/j.oftal.2013.09.003
[42]  
Arya SK, 2010, NEPAL J OPHTHALMOL, V2, P145, DOI 10.3126/nepjoph.v2i2.3722
[43]   OXIDATIVE REACTIONS IN THE TEAR FLUID OF PATIENTS SUFFERING FROM DRY EYES [J].
AUGUSTIN, AJ ;
SPITZNAS, M ;
KAVIANI, N ;
MELLER, D ;
KOCH, FHJ ;
GRUS, F ;
GOBBELS, MJ .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1995, 233 (11) :694-698
[44]   Diclofenac sodium, 0.1% (Voltaren ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis [J].
Avisar, R ;
Robinson, A ;
Appel, I ;
Yassur, Y ;
Weinberger, D .
CORNEA, 2000, 19 (02) :145-147
[45]   The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: A clinical and immunocytochemical study [J].
Avunduk, AM ;
Avunduk, MC ;
Varnell, ED ;
Kaufman, HE .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 136 (04) :593-602
[46]   High prevalence of sleep and mood disorders in dry eye patients: survey of 1,000 eye clinic visitors [J].
Ayaki, Masahiko ;
Kawashima, Motoko ;
Negishi, Kazuno ;
Tsubota, Kazuo .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 :889-894
[47]  
BACHMAN WG, 1985, INVEST OPHTH VIS SCI, V26, P1484
[48]   Allogeneic serum eye drops: time these became the norm? [J].
Badami, Krishna G. ;
McKellar, Malcolm .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2012, 96 (08) :1151-1152
[49]   Efficacy of 0.18% hypotonic sodium hyaluronate ophthalmic solution in the treatment of signs and symptoms of dry eye disease [J].
Baeyens, V. ;
Bron, A. ;
Baudouin, C. .
JOURNAL FRANCAIS D OPHTALMOLOGIE, 2012, 35 (06) :412-419
[50]   Tear Condition Following Unilateral Ptosis Surgery [J].
Bagheri, Abbas ;
Najmi, Hadi ;
Salim, Reza Erfanian ;
Yazdani, Shahin .
ORBIT-AN INTERNATIONAL JOURNAL ON ORBITAL DISORDERS AND FACIAL RECONSTRUCTIVE SURGERY, 2015, 34 (02) :66-71